I agree that, from the available data we have from previous trials, the chance for seeing improvement in eGFR is better than an improvement in MOCA scores. But I think that if RVX is going to soar in value, the MOCA data will be the driver....if eGFR data is all we have to hang our hat on, maybe we'll get back to where we were, maybe $3 to $4....that's my take right now but its just a guess.